☆ 4.3 Article

Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls

Freddy Caldera et al.

Summary: This study evaluated the humoral immunogenicity of mRNA COVID-19 vaccines in patients with IBD and healthy controls. The results showed that almost all IBD patients and healthy controls developed an antibody response after vaccination. However, IBD patients had lower antibody concentrations compared to the healthy controls, and those who received the Moderna vaccine had higher antibody concentrations. Patients on immune-modifying therapy had lower antibody concentrations.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases

Michael D. Kappelman et al.

Summary: Although most patients with IBD show an initial response to SARS-CoV-2 vaccination, older patients and those treated with anti-TNF and immunomodulator have blunted responses and may benefit from an additional vaccine dose. Patients treated with other classes of immunosuppressive medications have more robust initial immune responses to vaccination.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease

Evangelos Tsipotis et al.

Summary: The response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease (IBD) needs further investigation. This study observed the antibody response in 217 IBD patients over a period of 3 months after completing the standard two-dose mRNA vaccine series. The results showed that almost all (98.6%) IBD patients had a positive antibody response at least 3 months after vaccination, but a subset of patients on antitumor necrosis factor-alpha therapy had decreased antibody titers at 3 months. Approximately 10% of participants with high-titer antibodies at 1 month showed a decrease to low-positive titers at 3 months, mainly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

Sarah Frey et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Letter Gastroenterology & Hepatology

Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

Millie D. Long et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation

Raffi Lev-Tzion et al.

Summary: COVID-19 vaccine effectiveness in IBD patients is comparable to non-IBD controls and is not affected by treatment with TNF inhibitors or corticosteroids. The risk of IBD exacerbation did not differ between vaccinated and unvaccinated patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination

Paris Charilaou et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis

Anuraag Jena et al.

Summary: Complete COVID-19 vaccination is associated with seroconversion in most patients with IBD. The decay in titers over time necessitates consideration of additional doses in these patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany

Johanna Maria Classen et al.

Summary: The study aimed to investigate antibody response to SARS-CoV-2 vaccination in IBD patients on immunomodulators or biologics compared to healthy controls. Results showed a reduced antibody response in IBD patients but still relatively high antibody levels post vaccination.

DIGESTIVE DISEASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

Hadar Edelman-Klapper et al.

Summary: In this study, it was found that patients with IBD treated with anti-TNF alpha had lower serologic responses to the COVID-19 vaccine, as well as lower neutralizing and inhibitory functions. However, the vaccine was safe and did not affect the activity of IBD. It suggests that a booster dose should be considered for this group due to limited vaccine response longevity.

GASTROENTEROLOGY (2022)

添加到收藏夹

Letter Gastroenterology & Hepatology

Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD

Rosanna Cannatelli et al.

GUT (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study

Karin Cerna et al.

Summary: In this study, 602 IBD patients were vaccinated with BNT162b2, CX-024414, and ChAdOx1 nCoV-19 vaccines. The post-vaccine seropositivity rate among IBD patients was slightly lower than the control group. IBD recipients of the ChAdOx1 nCoV-19 vaccine had lower levels of anti-SARS-CoV-2 IgG compared to recipients of the other two vaccines and the control group, indicating the importance of mRNA vaccines for this specific group of patients.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID

Kimberly N. Weaver et al.

Summary: The severe acute respiratory syndrome coronavirus 2 vaccine is safe and well tolerated among individuals with inflammatory bowel disease (IBD) with low rates of adverse events and flare-ups.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey

Pierre Ellul et al.

Summary: Although IBD patients expressed concerns about the safety and efficacy of anti-SARS-CoV-2 vaccines, the survey showed that the implementation of vaccination among respondents was high, and the adverse events were comparable to the general population with minimal impact on their IBD.

JOURNAL OF CROHNS & COLITIS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]

Jayne Doherty et al.

Summary: Patients with inflammatory bowel disease (IBD) have attenuated antibody responses to COVID-19 vaccination, and the use of TNF antagonists exacerbates this effect. Patients who do not seroconvert following vaccination are particularly vulnerable. Our study highlights the importance of booster vaccination programs for patients with IBD.

JOURNAL OF CROHNS & COLITIS (2022)

添加到收藏夹

Review Medicine, General & Internal

SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis

Kuan-Yi Sung et al.

Summary: SARS-CoV-2 vaccination is effective and well-tolerated in preventing COVID-19 infections in inflammatory bowel disease (IBD) patients. The rate of COVID-19 infection after vaccination is comparable between IBD patients and non-IBD patients, while the rate is higher in unvaccinated IBD patients. Over 98% of IBD patients had seroconversion after receiving all doses of the vaccine.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study

James L. Alexander et al.

Summary: The study found that the immunogenicity of COVID-19 vaccines varies in patients with inflammatory bowel disease (IBD) depending on the immunosuppressive drugs they are on. Patients treated with infliximab, infliximab plus thiopurines, and tofacitinib had lower antibody concentrations, while there were no significant differences in patients treated with thiopurines, ustekinumab, and vedolizumab compared to healthy controls.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?

Tarun Chhibba et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2

Richard Vollenberg et al.

Summary: This study investigated the humoral response in immunosuppressed IBD patients after COVID-19 mRNA vaccination and found lower antibody levels and neutralizing capacity in these patients 3 and 6 months after the second vaccination. Patients treated with anti-TNF agents may require early booster shots.

BIOMEDICINES (2022)

添加到收藏夹

Review Immunology

Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis

Anuraag Jena et al.

Summary: The treatment for COVID-19 often involves immune-modulating drugs, which are also used in immune mediated inflammatory diseases (IMIDs). This systematic review examines the seroconversion after SARS-CoV-2 vaccination in patients with IMIDs and the impact of different drugs on seroconversion rates. The findings suggest that patients with IMIDs have lower seroconversion rates, and certain therapies have no impact on seroconversion rates while others result in poorer responses.

AUTOIMMUNITY REVIEWS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease

Joelynn Dailey et al.

Summary: The study found that IBD patients receiving biologic therapies have lower and less durable neutralizing antibody response to natural infection with SARS-CoV-2, putting them at risk of reinfection. However, after vaccination, patients had a significantly stronger antibody response to SARS-CoV-2, indicating potential protection against the virus.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

Neil Chanchlani et al.

Summary: Anti-TNF treatment is associated with lower seroprevalence of SARS-CoV-2 nucleocapsid antibodies and antibody reactivity compared to vedolizumab-treated patients. Higher seropositivity rates in patients with undetectable anti-TNF levels suggest a causal relationship, though other factors like combination therapy with immunomodulators may have influenced the results.

JOURNAL OF CROHNS & COLITIS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Simeng Lin et al.

Summary: This study reports immune responses and breakthrough infections in patients with inflammatory bowel disease receiving anti-TNF treatments after receiving COVID-19 vaccination, and suggests the need for adapted vaccination schedules for these patients.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease

P. A. Reuken et al.

Summary: The study found that IBD patients showed significant T cell responses after receiving the first dose of the SARS-CoV-2 vaccine, even in the absence of antibodies. Additionally, after the second dose of vaccination, a majority of IBD patients showed an increase in humoral immune response.

JOURNAL OF CROHNS & COLITIS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Corey A. Siegel et al.

GUT (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

James L. Alexander et al.

Summary: SARS-CoV-2 vaccination in patients with IBD is supported due to anticipated low risks, despite some concerns that protective immune responses may be diminished in certain patients. Further research is needed to address vaccine hesitancy, the impact of immunosuppression, and the search for predictive biomarkers of vaccine success.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Serre-Yu Wong et al.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Nicholas A. Kennedy et al.

Summary: The study found that patients with inflammatory bowel disease treated with infliximab had attenuated serological responses to SARS-CoV-2 infection. Additionally, the serological response to SARS-CoV-2 infection in the infliximab-treated group was further blunted by concomitant use of immunomodulators.

GUT (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Mohammad Shehab et al.

Summary: Patients with inflammatory bowel disease (IBD) receiving infliximab combination therapy had lower levels of SARS-CoV2 IgG, IgA, and neutralizing antibodies after BNT162b2 vaccination compared with healthy participants. However, most patients treated with infliximab combination therapy seroconverted after two doses of the vaccine.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges

Judith Wellens et al.

Summary: Patients with inflammatory bowel diseases (IBD) have been considered high-risk for COVID-19 infection and complications since the start of the pandemic. However, they were excluded from clinical phase III vaccine trials, leading to challenges in assessing the effectiveness of new vaccines. Adapted vaccination strategies may be needed for some IBD patients to optimize immune response. Therefore, further research is needed to develop tailored vaccination plans for IBD patients.

JOURNAL OF CROHNS & COLITIS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Review Article: Vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic

Jayne Doherty et al.

Summary: Patients with IBD have reduced immune responses following vaccination, especially when receiving anti-TNF therapy which may decrease antibody titres to COVID-19 vaccines. It is recommended that IBD patients be vaccinated at the earliest opportunity, ideally in remission with minimized corticosteroid dose before vaccination. Further research is needed to explore the impact of different biologics on vaccine response to COVID-19 in the IBD population and the potential for booster vaccines or heterologous prime-boost vaccinations.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease

Gregory J. Botwin et al.

Summary: Patients with immune-mediated inflammatory diseases like IBD who are on immunosuppressive and biologic therapies were largely excluded from COVID-19 mRNA vaccine trials. A study on 246 adults with IBD found that adverse events after mRNA vaccination were similar to the general population. Adverse events were more common in younger patients and those with previous COVID-19, but less common in individuals receiving advanced therapies with biologics or small-molecule inhibitors.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations

Sanjay K Murthy et al.

Journal of the Canadian Association of Gastroenterology (2021)

添加到收藏夹

Letter Gastroenterology & Hepatology

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Valeriya Pozdnyakova et al.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications

Nabeel Khan et al.

Summary: The study found that full vaccination against SARS-CoV-2 has an effectiveness of approximately 80.4% in patients with inflammatory bowel disease who may be taking immunosuppressive medications.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients

Elizabeth A. Spencer et al.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination for Paediatric Patients With Inflammatory Bowel Diseases

Gigi Veereman et al.

Summary: The Porto group members provide current evidence on vaccinating children and young adolescents with IBD against SARS-CoV-2, aiming to address concerns from parents and adolescents.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions

Dan Turner et al.

INFLAMMATORY BOWEL DISEASES (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study

Dan Turner et al.

GASTROENTEROLOGY (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.